Adding Regorafenib in First-Line 'Promising' in Gastric Cancer
(MedPage Today) -- Adding regorafenib (Stivarga) to a standard first-line chemoimmunotherapy regimen for HER2-negative metastatic esophagogastric cancer demonstrated "promising" activity in a single-arm phase II study, according to researchers... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 6, 2023 Category: Gastroenterology Source Type: news
Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
FRIDAY, Sept. 1, 2023 -- For patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma, zolbetuximab, a monoclonal antibody that... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
Guiding Light: Practical Perspectives of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer Guiding Light: Practical Perspectives of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
Expert perspectives on the patient-centric management of HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors, latest clinical data and its relevance to daily practice.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Episode 4: Breakthroughs in HER2-Amplified Colorectal Cancer Episode 4: Breakthroughs in HER2-Amplified Colorectal Cancer
Drs Benjamin L. Schlechter and John Strickler discuss the newest testing and treatment options for HER2-amplified colorectal cancer and the findings from the MOUNTAINEER and DESTINY-CRC studies.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 1, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
New Test for HER2+ Breast Cancer to Personalize Therapy New Test for HER2+ Breast Cancer to Personalize Therapy
The multiparameter molecular classifier test has a high negative predictive value (NPV), underscoring its accuracy for identifying patients who may not be good candidates for treatment de-escalation.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Continuing Trastuzumab After Progression Shows Promise in HER2+ Gastric/GEJ Cancer
(MedPage Today) -- Continuing trastuzumab (Herceptin)-containing therapy beyond progression led to encouraging progression-free survival (PFS) and overall survival (OS) rates in advanced HER2-positive gastric/gastroesophageal junction (GEJ) cancer... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 28, 2023 Category: Gastroenterology Source Type: news
Don ’t Let Breast Cancer Subtype Guide Mastectomy Choice, Doctors Say
Research from ASCO 2023 finds people are opting for mastectomies more frequently if they have HER2-positive breast cancer. The data sheds light on the problem with choosing mastectomy based on the type of cancer you have. (Source: WebMD Health)
Source: WebMD Health - June 23, 2023 Category: Consumer Health News Source Type: news
Experts & Docs Disagree on Treatment of Early Breast Cancer Experts & Docs Disagree on Treatment of Early Breast Cancer
Nearly 60% of health care providers surveyed failed to choose the same treatment strategies for HER2 –early breast cancer.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Some Breast Cancer Patients May Safely Forgo Chemotherapy
Researchers are looking for less aggressive cancer therapies that won't affect odds of survival. One new study shows HER2-positive breast cancer patients were successfully treated without chemotherapy. (Source: WebMD Health)
Source: WebMD Health - June 15, 2023 Category: Consumer Health News Source Type: news
Glenmark Pharma slashes price of breast cancer drug Trastuzumab
Trastuzumab is used in the treatment of a particular type of breast cancer -- HER2-positive, and the company markets its version in India under the brand name 'Trumab'. It is now priced at Rs 15,749 for a 440 mg vial from Rs 54,000 earlier. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 15, 2023 Category: Pharmaceuticals Source Type: news
Antibody Treatment Could Fight Rare But Deadly Bile Duct Cancers
MONDAY, June 12, 2023 -- Patients with bile duct cancer might soon have an additional treatment available to them, thanks to a newly discovered tumor target.
Some bile duct cancers are driven by a mutated HER2 gene, which has also been implicated in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 12, 2023 Category: General Medicine Source Type: news
Antibody Treatment Zanidatamab Could Fight Rare But Deadly Bile Duct Cancers
MONDAY, June 12, 2023 -- Patients with bile duct cancer might soon have an additional treatment available to them, thanks to a newly discovered tumor target.
Some bile duct cancers are driven by a mutated HER2 gene, which has also been implicated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 12, 2023 Category: General Medicine Source Type: news
